(91), where SHP2 inhibition prevents the reactivation of RAS and ERK1/2 following treatment with intermediate degenerative lymphoma kinase (ALK) inhibitors in NSCLC, the synergistic impact of combined RTK and SHP2 inhibitors appears to be a more general effect. Here, PTPN11 is linked to non-small cell lung carcinoma.